BiotechTube
Metavention

Metavention

Minneapolis, United States· Est.
metavention.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $65M

Overview

Metavention is a private, pre-revenue biotech company founded in 2010 and headquartered in Minneapolis, USA. It is advancing a catheter-based radiofrequency denervation platform targeting the sympathetic nervous system to treat hypertension and type 2 diabetes. The company is currently conducting multiple early-stage clinical studies (DeLIVER and MODUS) in the U.S., Australia, and New Zealand to evaluate the safety and performance of its iRF Denervation System for both renal and hepatic nerve ablation.

CardiovascularMetabolic

Technology Platform

iRF Denervation System: a catheter-based platform delivering radiofrequency energy to permanently ablate overactive sympathetic nerves around the renal arteries (for hypertension) and the common hepatic artery (for type 2 diabetes).

Funding History

2
Total raised:$65M
Series B$40M
Series A$25M

Opportunities

The massive, global patient populations with uncontrolled hypertension and type 2 diabetes represent a multi-billion dollar market opportunity for a one-time, device-based therapy.
Success in hepatic denervation could establish a first-in-class, disease-modifying treatment for diabetes, a particularly high-value and disruptive prospect.

Risk Factors

Key risks include the clinical failure to demonstrate sufficient efficacy or durability in ongoing and future trials, regulatory hurdles for a novel device-based metabolic treatment, and intense competition from larger, well-capitalized medtech companies with approved or advanced renal denervation systems.

Competitive Landscape

Metavention competes in the renal denervation space with established players like Medtronic (Symplicity Spyral), Recor Medical (Paradise, now part of Otsuka), and Boston Scientific. Its differentiation is the pursuit of hepatic denervation for diabetes and a platform capable of multi-organ ablation, but it faces the challenge of entering a market where larger competitors have significant commercial and clinical trial resources.

More companies in Neuroscience & CNS →More companies in United States →